Journal Review 2024: VISION Trial: Lutetium-177 PSMA 617 for Metastatic Castration-Resistant Prostate Cancer

Course overview

UAN: 0018-0000-24-224-H01-P & T RELEASE: 12/01/2024 EXPIRE: 12/01/2025 CREDITS: 1.5 LEARNING OBJECTIVES: 1. Review the rationale for the VISION trial in metastatic castration resistant prostate cancer 2. Describe the patient inclusion criteria for the VISION trial 3. Recognize the key aspects of the VISION trial design 4. Identify key endpoints of the VISION trial NOTE: An annual subscription for Purdue's nuclear pharmacy re-certification program provides access to both the continuing education component of the program and the "Radiopharmacy Portal" a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $225 for nuclear pharmacists and $125 for nuclear pharmacy technicians.